Would you give ADT + docetaxel -> darolutamide for a low risk castrate sensitive metastatic prostate cancer patient given ARASENS results?

ARASENS was designed during the era of docetaxel plus ADT emerging as the standard of care for men with mHSPC irrespective of disease volume, based on the improved OS observed in STAMPEDE for a largely de novo mHSPC patient population, where there was no heterogeneity observed for the OS benefit in ...

I take the question to mean would I treat a patient with low volume mCSPC with ADT + darolutamide + docetaxel. This is a complicated question because a similar trial, the PEACE-1 trial assessed the addition of abiraterone to ADT + docetaxel in mCSPC in a randomized fashion. In a prespecified subset ...